RT Journal Article
SR Electronic
T1 Directional anchor genes refine polygenic informed treatment selection in schizophrenia and bipolar disorder
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.03.20.22272666
DO 10.1101/2022.03.20.22272666
A1 Reay, William R.
A1 Geaghan, Michael P.
A1 Atkins, Joshua R.
A1 Carr, Vaughan J.
A1 Green, Melissa J.
A1 Cairns, Murray J.
YR 2022
UL http://medrxiv.org/content/early/2022/03/22/2022.03.20.22272666.abstract
AB Genetically informed drug development and repurposing is an attractive prospect for improving outcomes in patients with psychiatric illness; however, the effectiveness of these endeavours can be confounded by heterogeneity. In this study, we propose a novel approach that links interventions implicated by disorder-associated genetic risk, at the population level, to a framework that can target these compounds to individuals. Specifically, results from genome-wide association studies are integrated with expression data to prioritise individual “directional anchor” genes for which the predicted risk-increasing direction of expression could be counteracted by an existing drug. While these compounds represent plausible therapeutic candidates, they are not likely to be equally efficacious for all individuals. To account for this heterogeneity, we constructed polygenic scores restricted to variants annotated to the network of genes that interact with each directional anchor gene. These metrics, we call pharmagenic enrichment scores (PES), identify individuals with a higher burden of genetic risk, localised in biological processes related to the candidate drug target, to inform precision drug repurposing. We used this approach to investigate schizophrenia and bipolar disorder and reveal several compounds targeting specific directional anchor genes that could be plausibly repurposed, including antioxidants, vitamins, antiarrhythmics, and lipid modifying agents. These genetic risk scores, mapped to the networks associated with target genes, revealed biological insights that cannot be observed in undifferentiated genome-wide polygenic risk score (PRS). For example, an enrichment of these partitioned scores in schizophrenia cases with otherwise low PRS and distinct correlations with measured biochemical traits. In summary, genetic risk could be used more specifically to direct drug repurposing candidates that target particular genes implicated in psychiatric and other complex disorders.Competing Interest StatementW.R.R and M.J.C have filed a patent related to the pharmagenic enrichment score approach (WIPO Patent Application: WO/2020/237314). The remaining authors declare no competing financial interests.Funding StatementThis work was supported by a National Health and Medical Research Council (NHMRC) grant (1188493). M.J.C. is supported by an NHMRC Senior Research Fellowship (1121474), URL: https://www.nhmrc.gov.au/. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the paper. W.R.R was supported by an Australian Government Research Training Program Stipend.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Hunter New England Human Research Ethics CommitteeI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe analysis code for this study can be found in the following GitHub repository: https://github.com/Williamreay/Directional_anchor_gene_psyciatric_PES. Researchers can access the full UK Biobank data upon approval (https://www.ukbiobank.ac.uk/enable-your-research/apply-for-access). The ASRB cohort is available upon reasonable request and ethics approval (https://www.neura.edu.au/discovery-portal/asrb/). The remaining data are all publicly available, as outlined in the studies cited at relevant positions throughout the main text. https://www.ukbiobank.ac.uk/enable-your-research/apply-for-access https://www.neura.edu.au/discovery-portal/asrb/